(All fields required)
Please enter a valid email.
Please enter your name.
What is : (So we know you are human.)
Please supply the correct answer.
Chie Emoto, PhD
studies physiologically-based pharmacokinetics modeling. Her studies allow us to visualize the relationship between ontogeny profiles of drug-metabolizing enzymes/transporters and their pharmacogenetics. This model supports improving clinical outcomes and reducing adverse side-effects in pediatric patients. Her expertise also includes drug metabolism studies; pharmacokinetic analysis; and analytical pharmacology.
Assistant Professor, UC Department of Pediatrics
Pediatric physiological based pharmacokinetics modeling; ontogeny of drug metabolizing enzymes and transporters
MS: Graduate School of Pharmaceutical Science, Kanazawa University, Ishikawa, Japan, 2000.
PhD: Show Pharmaceutical University, Tokyo, Japan, 2006.
Emoto C, Fukuda T, Venkatasubramanian R, Vinks AA. The impact of CYP3A5*3 polymorphism on sirolimus pharmacokinetics: Novel insights from a physiologically-based pharmacokinetics (PBPK) modeling approach. British Journal of Clinical Pharmacology. 2015;80:1438-1446.
Emoto C, Fukuda T, Johnson TN, Adams DM, Vinks AA. Development of a Pediatric Physiologically Based Pharmacokinetic Model for Sirolimus: Applying Principles of Growth and Maturation in Neonates and Infants. CPT Pharmacometrics Syst Pharmacol. 2015;4:e17.
Vinks AA, Emoto C, Fukuda T. Modeling and simulation in pediatric drug therapy: Application of pharmacometrics to define the right dose for children. Clinical Pharmacology and Therapeutics. 2015;98:298-308.
Nakamaru Y, Emoto C, Shimizu M, Yamazaki H. Human pharmacokinetic profiling of the dipeptidyl peptidase-IV inhibitor teneligliptin using physiologically based pharmacokinetic modeling. Biopharmaceutics & Drug Disposition. 2015;36:148-162.
Emoto C, Fukuda T, Mizuno T, Cox S, Schniedewind B, Christians U, Widemann BC, Fisher MJ, Weiss B, Perentesis J, Vinks AA. Age dependent changes in metabolite formation of sirolimus in patients with neurofibromatosis type 1. Therapeutic Drug Monitoring. 2015;37:359-399.
Emoto C, Fukuda T, Cox S, Christians U, Vinks AA. Development of a physiologically-based pharmacokinetic model for sirolimus: predicting bioavailability based on intestinal CYP3A content. CPT: Pharmacometrics & Systems Pharmacology. 2013;2:e59.
Emoto C, Yoda N, Uno Y, Iwasaki K, Umehara K, Kashiyama E, Yamazaki H. Comparison of p450 enzymes between cynomolgus monkeys and humans: p450 identities, protein contents, kinetic parameters, and potential for inhibitory profiles. Current Drug Metabolism. 2013;14:239-252.
Yoda N, Emoto C, Date S, Kondo S, Miyake M, Nakazato S, Umehara K, Kashiyama E. Characterization of intestinal and hepatic P450 enzymes in cynomolgus monkeys with typical substrates and inhibitors for human P450 enzymes. Xenobiotica. 2012;42:719-730.
Emoto C, Murayama N, Rostami-Hodjegan A, Yamazaki H. Methodologies for investigating drug metabolism at the early drug discovery stage: prediction of hepatic drug clearance and P450 contribution. Current Drug Metabolism. 2010;11:678-85.
Emoto C, Murayama N, Rostami-Hodjegan A, Yamazaki H. Utilization of estimated physicochemical properties as an integrated part of predicting hepatic clearance in the early drug-discovery stage: Impact of plasma and microsomal binding. Xenobiotica. 2009;39:227-235.
Tsuyoshi Fukuda, PhD
is director of the pharmacogenetics laboratory in the Division of Clinical Pharmacology. He focuses on drug metabolizing enzyme and transporter genetic variants, PK and response to medication and adverse drug events. He has developed innovative approaches in pharmacogenetic assay development, data analyses, integrated PK/PD/PG modeling of the clinical data set, and physiologically based pharmacokinetic (PBPK) analysis and model development.
Associate Professor, UC Department of Pediatrics
Clinical pharmacology (pharmacogenetics, pharmacokinetics and pharmacodynamics)
Dr. Fukuda received his pharmacy degree and PhD in pharmaceutical science from Osaka University, Japan. He received postdoctoral training in the Division of Clinical Pharmacology and Pharmacogenomics (Prof. J. Azuma, MD) and served as an assistant professor at Osaka University, Graduate School of Pharmaceutical Sciences. He joined the Division of Clinical Pharmacology (Prof. Alexander A. Vinks, PharmD, PhD) at Cincinnati Children's Hospital Medical Center in 2007. He spent around 20 years in the field of clinical pharmacology while engaged in pharmacogenetic (PG) and pharmacokinetic-pharmacodynamic (PK/PD) research. His current research interests include the clinical application of integrated PK/PD/PG modeling and simulation and physiologically based pharmacokinetic (PBPK) analysis with developmental pharmacology, focusing on improving our understanding of inter-patient differences in drug response and developing individualized dosing strategies in pediatric patients.
Dr. Fukuda’s efforts have resulted in over 70 peer-reviewed publications with project members that include master's and PhD students, research fellows, clinical fellows, pharmacists, physicians, and private sector R & D staff.
BS: Osaka University, School of Pharmacy, Osaka, Japan, 1995.
Pharmacist: Japan, 1995.
MS: Osaka University, Osaka, Japan, 1997.
PhD: Osaka University, Osaka, Japan, 2000.
Certification: Clinical Pharmacology (Pharmacist), 2003 (Japanese Society of Clinical Pharmacology), 2008 renewed.
Jodele S, Fukuda T, Mizuno K, Vinks AA, Laskin BL, Goebel J, Dixon BP, Chima RS, Hirsch R, Teusink A, Lazear D, Lane A, Myers KC, Dandoy CE, Davies SM. Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2016 Feb;22(2):307-15.
Emoto C, Fukuda T, Johnson TN, Adams DM, Vinks AA. Development of a Pediatric Physiologically Based Pharmacokinetic Model for Sirolimus: Applying Principles of Growth and Maturation in Neonates and Infants. CPT Pharmacometrics Syst Pharmacol. 2015 Feb;4(2):e17.
Emoto C, Fukuda T, Venkatasubramanian R, Vinks AA. The impact of CYP3A5*3 polymorphism on sirolimus pharmacokinetics: insights from predictions with a physiologically-based pharmacokinetic model. Br J Clin Pharmacol. 2015 Dec;80(6):1438-46.
Vinks AA, Emoto C, Fukuda T. Modeling and simulation in pediatric drug therapy: Application of pharmacometrics to define the right dose for children. Clin Pharmacol Ther. 2015 Sep;98(3):298-308.
Jodele S, Fukuda T, Vinks A, Mizuno K, Laskin BL, Goebel J, Dixon BP, Teusink A, Pluthero FG, Lu L, Licht C, Davies SM. Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Biol Blood Marrow Transplant. 2014 Apr;20(4):518-25.
Mizuno T, Fukuda T, Masuda S, Uemoto S, Matsubara K, Inui KI, Vinks AA. Developmental trajectory of intestinal MDR1/ABCB1 expression in children. Br J Clin Pharmacol. 2014 May;77(5):910-2.
Dong M, Fukuda T, Vinks AA. Optimization of mycophenolic acid therapy using clinical pharmacometrics. Drug Metab Pharmacokinet. 2014;29(1):4-11.
Emoto C, Fukuda T, Cox S, Christians U, Vinks AA. Development of a physiologically-based pharmacokinetic model for sirolimus: predicting bioavailability based on intestinal CYP3A content. CPT Pharmacometrics Syst Pharmacol. 2013 Jul 24;2:e59.
Fukuda T, Chidambaran V, Mizuno T, Venkatasubramanian R, Ngamprasertwong P, Olbrecht V, Esslinger HR., Vinks AA, Sadhasivam S. Organic Cation Transporter 1 Genetic Variants influence the pharmacokinetics of Morphine in Children. Pharmacogenomics. 2013 Jul;14(10):1141-51.
Shimamoto Y, Fukuda T, Tanaka K, Komori K, Sadamitsu D. Systemic inflammatory response syndrome criteria and vancomycin dose requirement in patients with sepsis. Intensive Care Med. 2013 Jul;39(7):1247-52.
Alexander (Sander) A. Vinks, PharmD, PhD, FCP Director, Division of Clinical Pharmacology
is interested in population and physiologically based PK/PD modeling, pharmacogenetics (PG) and the application of genomic, population and simulation approaches (pharmacometrics) to pediatric clinical trial design and the development of Bayesian dosing algorithms. He is program director of the Cincinnati Training Program in Pediatric Clinical and Developmental Pharmacology and a founder and co-director of the Genetic Pharmacology Service.
Director, Division of Clinical Pharmacology
Scientific Director, Pharmacy Research, Research in Patient Services
Professor, UC Department of Pediatrics
Adjunct Professor of Pharmacology
Sander Vinks, PharmD, PhD, FCP, is a professor of pediatrics and pharmacology at the University of Cincinnati, College of Medicine. He is the director of the Division of Clinical Pharmacology, and serves as director of the Pediatric Clinical and Developmental Pharmacology NIH T32 training program since 2011. He is co-director of Cincinnati Children’s Genetic Pharmacology Service, and scientific director for pharmacy research in the Division of Patient Services. He also directs the Laboratory of Applied Pharmacokinetics and Pharmacogenetics (LAPP) and a multidisciplinary Pharmacometrics Core. Dr. Vinks also serves as an advisor on an FDA pediatric sub-committee.
Dr. Vinks is the past president of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. He serves on the Board of Regents of the American College of Clinical Pharmacology and is chair of the Clinical Pharmacology and Translational Research Committee of the American Association of Pharmaceutical Scientists. He has served as the principal investigator of the former NICHD Pediatric Research Unit at Cincinnati Children’s Hospital Medical Center.
His major research interests include personalized and precision medicine, pharmacokinetic-pharmacodynamic (PK/PD) modeling, physiologically based pharmacokinetics (PBPK), pharmacogenetics/genomics (PG) and the application of genomic, population and simulation approaches (pharmacometrics) to pediatric trial design and therapeutic drug management.
Dr. Vinks has presented his research as an invited speaker in 220 national and international conferences, has published over 140 peer reviewed manuscripts and 18 book chapters and has presented more than 150 abstracts. He is associate editor of Clinical Pharmacology & Therapeutics. Dr. Vinks is both board certified in clinical pharmacology and toxicology and is a fellow of the American College of Clinical Pharmacology.
Certification: American Board of Clinical Pharmacology, 2001.
PhD: Clinical Pharmacology, Leiden University, Leiden The Netherlands, 1996.
PharmD: Hospital Pharmacy, The Hague Central Hospital Pharmacy, The Hague, The Netherlands, 1986.
MS: Pharmacology, University of Toronto, Toronto Canada, 1983.
MS: Pharmacy, Leiden University, Leiden, The Netherlands, 1981.
Wiles JR, Isemann B, Ward LP, Vinks AA, Akinbi H. Current management of neonatal abstinence syndrome secondary to intrauterine opioid exposure. J Pediatr. 2014 Sep;165(3):440-6.
Hahn A, Frenck RW Jr, Zou Y, Vinks AA. Validation of a Pediatric Population Pharmacokinetic Model for Vancomycin. Ther Drug Monit. 2014 Nov 21.
Nehus EJ, Mouksassi S, Vinks AA, Goldstein S. Meropenem in Children Receiving Continuous Renal Replacement Therapy: Clinical Trial Simulations Using Realistic Covariates. Journal Clin Pharmacology. 2014 Dec;54(12):1421-1428.
Smits TA, Cox S, Fukuda T, Sherbotie JR, Ward RM, Goebel J, Vinks AA. Effects of unbound mycophenolic Acid on inosine monophosphate dehydrogenase inhibition in pediatric kidney transplant patients. Ther Drug Monit. 2014 Dec;36(6):716-23.
Dong M, Fukuda T, Cox S, de Vries MT, Hooper DK, Goebel J, Vinks AA. Population pharmacokinetic-pharmacodynamic modelling of mycophenolic acid in paediatric renal transplant recipients in the early post-transplant period. Br J Clin Pharmacol. 2014 Nov;78(5):1102-12.
Rasmussen-Torvik LJ, Stallings SC, Gordon AS, et al. Design and anticipated outcomes of the eMERGE-PGx project: a multicenter pilot for preemptive pharmacogenomics in electronic health record systems. Clin Pharmacol Ther. 2014 Oct;96(4):482-9.
Emoto C, Fukuda T, Mizuno T, Cox S, Schniedewind B, Christians U, Widemann BC, Fisher MJ, Weiss B, Perentesis J, Vinks AA. Age dependent changes in sirolimus metabolite formation in patients with neurofibromatosis type 1. Ther Drug Monitoring. 2014 Aug 26.
Venkatasubramanian R, Fukuda T, Niu J, Mizuno T, Chidambaran V, Vinks AA, Sadhasivam S. ABCC3 and OCT1 genotypes influence pharmacokinetics of morphine in children. Pharmacogenomics. 2014 Jul;15(10):1297-309.
Roberts JA, Abdul-Aziz MH, Lipman J, Mouton JW, Vinks AA, Felton TW, Hope WW, Farkas A, Neely MN, Schentag JJ, Drusano G, Frey OR, Theuretzbacher U, Kuti JL; on behalf of The International Society of Anti-Infective Pharmacology and the Pharmacokinetics and Pharmacodynamics Study Group of the European Society of Clinical Microbiology and Infectious Diseases. Individualized antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014 Jun;14(6):498-509.
Vidya Chidambaran, MD Anesthesiologist, Department of Anesthesia
is a pediatric anesthesiologist and acute pain physician with special interests in personalization of pediatric analgesia and opioid pharmacogenomics, optimization of drug (propofol) dosing in morbidly obese children by study of pharmacokinetics/pharmacodynamics, evaluation of factors leading to persistent postoperative pain and use of capnography for early detection of opioid induced respiratory depression.
Anesthesiologist, Department of Anesthesia
Associate Professor, UC Department of Anesthesiology
MBBS: Medicine,Bangalore Medical College, India, 1997.
MD: Anesthesiology, Kasturba Medical College, India, 1998-2001.
Internship: Anesthesiology, Jackson Memorial Hospital, Miami, Florida, 2003-2004.
Residency: Anesthesiology, Brookdale University Hospital, Brooklyn, New York, 2004-2007.
Fellowship: Pediatric Anesthesia, Johns Hopkins Hospital, Baltimore, Maryland, 2007-2008.
Sadhasivam S, Fukuda T, Chidambaran V, Mizuno T, Venkatasubramanian R, Ngamprasertwong P, Olbrecht V, Esslinger H, Vinks AA. OCT1 Genetic Variants influence the pharmacokinetics of morphine in children. Pharmacogenomics. 2013 Jul;14(10):1141-51.
Chidambaran V, Sadhasivam S, Diepstraten J, Esslinger H, Cox S, Schnell BM, Samuels P, Inge T, Vinks AA, Knibbe CA. Evaluation of propofol anesthesia in morbidly obese children and adolescents. BMC Anesthesiology 2013, 13:8.
Chidambaran V, Gentry C, Ajuba-Iwuji C, Sponsellar PD, Ain M, Lin E, Zhang X, Klaus SA, Njoku DB. A Retrospective identification of gastroesophageal reflux disease as a new risk factor for surgical site infection in cerebral palsy patients after spine surgery. Anesth Analg. 2013 117(1):162-8.
Chidambaran V, Mahmoud M, Sadhasivam S. Risk for Peroneal Nerve Injury After Femur Osteosarcoma Resection: Is regional analgesia safe? J Clin Anesth. 2013 Feb;25(1):76-8.
Sadhasivam S and Chidambaran V. Pharmacogenomics of Opioids and Perioperative Pain Management. Pharmacogenomics. 2012 Nov;13(15):1719-40.
V Chidambaran, S Sadhasivam. Pediatric Acute and Surgical Pain Management: Recent Advances and Future Perspectives. "Contemporary Topics in Pediatric Anesthesiology" in International Anesthesiology Clinics 2012 Fall; 50(4):66-82.
Sadhasivam S, Krekels E, Chidambaran V, Esslinger H, Zhang K, Fukuda T, Vinks AA. Morphine Clearance in Children: Does Race or Genetics Matter? J Opioid Manag. 2012 Jul-Aug;8(4):217-26.
Chidambaran V, Rosing J, Soler X, Sadhasivam S. Muscle Trauma from Tourniquet (Mis)Use. Anesthesiology. 2012 Jul;117(1):179.
Diepstraten J, Chidambaran V, Sadhasivam S, Esslinger H, Cox S, Inge T, Knibbe CAJ, Vinks AA. Propofol Clearance in Morbidly Obese Children and Adolescents. Clin Pharmacokinet. 2012 Aug 1:51(8):543-51.
Sadhasivam S, Chidambaran V, Ngamprasertwong P, Esslinger H, Prows C, Zhang X, Martin LJ, McAuliffe J. Race and Unequal Burden of Perioperative Pain and Opioid Related Adverse Effects in African-American and Caucasian Children. Pediatrics. 2012 May;129(5):832-8.
Tracy A. Glauser, MD Associate Director, Cincinnati Children's Research Foundation
Associate Director, Cincinnati Children's Research Foundation
Director, Comprehensive Epilepsy Center
Co-Director, Genetic Pharmacology Service
Epilepsy; pharmacogenetics; clinical pharmacology
Tracy A. Glauser, MD, is director of the Comprehensive Epilepsy Center and co-director of the Genetic Pharmacology Service at Cincinnati Children’s Hospital Medical Center and professor of pediatrics in the University of Cincinnati College of Medicine. Dr. Glauser received his medical degree, cum laude, from Jefferson Medical College in Philadelphia, PA. He completed his residency in pediatrics at the John Hopkins Hospital in Baltimore, MD, and fellowship in child neurology at The Children’s Hospital of Philadelphia, University of Pennsylvania in Philadelphia, PA. Dr. Glauser completed a National Institute of Neurological Disorders and Stroke research fellowship in pediatric neurology and was a fellow in epilepsy and electroencephalography at St. Louis Children’s Hospital, Washington University School of Medicine in St. Louis, Missouri.
Dr. Glauser has authored and co-authored more than 130 articles and book chapters, been involved with the development of six evidence-based guidelines about epilepsy therapy and given over 150 invited lectures throughout the world. He has been the principal investigator on multiple NIH grants. Currently, Dr. Glauser directs the NIH funded Childhood Absence Epilepsy clinical trial involving 32 pediatric centers around the United States. Dr. Glauser’s fields of expertise are pediatric neurology, pediatric epilepsy, clinical pharmacology and pharmacogenetics.
MD: Jefferson Medical College, Philadelphia, PA, 1985.
Residency: Johns Hopkins Hospital, Baltimore, MD.
Fellowship: St. Louis Children's Hospital, St. Louis, MO.
Certification: Pediatrics, 1990; Neurology (with special competence in child neurology), 1991.
Modi AC, Guilfoyle SM, Morita DA, Glauser TA. Development and reliability of a correction factor for parent-reported adherence to pediatric antiepileptic drug therapy. Epilepsia. 2010 Nov 18. doi: 10.1111/j.1528-1167.2010.02789.x.
Modi AC, Monahan S, Daniels D, Glauser TA. Development and validation of the Pediatric Epilepsy Medication Self-Management Questionnaire. Epilepsy Behav. 2010 May;18(1-2):94-9
Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, Clark PO, Capparelli EV, Adamson PC; Childhood Absence Epilepsy Study Group. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med. 2010 Mar 4;362(9):790-9.
Holland KD, Monahan S, Morita D, Vartzelis G, Glauser TA. Valproate in children with newly diagnosed idiopathic generalized epilepsy. Acta Neurol Scand. 2010 Mar;121(3):149-53.
Pestian J, Spencer M, Matykiewicz P, Zhang K, Vinks AA, Glauser T. Personalizing Drug Selection Using Advanced Clinical Decision Support. Biomed Inform Insights. 2009 Jun 23;2:19-29.
Prows CA, Nick TG, Saldaña SN, Pathak S, Liu C, Zhang K, Daniels ZS, Vinks AA, Glauser TA. Drug-metabolizing enzyme genotypes and aggressive behavior treatment response in hospitalized pediatric psychiatric patients. J Child Adolesc Psychopharmacol. 2009 Aug;19(4):385-94.
Modi AC, King AS, Monahan SR, Koumoutsos JE, Morita DA, Glauser TA. Even a single seizure negatively impacts pediatric health-related quality of life. Epilepsia. 2009 Sep;50(9):2110-6.
Daniels ZS, Nick TG, Liu C, Cassedy A, Glauser TA. Obesity is a common comorbidity for pediatric patients with untreated, newly diagnosed epilepsy. Neurology. 2009 Sep 1;73(9):658-64.
Glauser TA, Sankar R; Co-chairs of the Leadership in Epilepsy, Advocacy, and Development Faculty. Core elements of epilepsy diagnosis and management: expert consensus from the Leadership in Epilepsy, Advocacy, and Development (LEAD) faculty. Curr Med Res Opin. 2008 Dec;24(12):3463-77.
Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, Arroyo S. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology. 2008 May 20;70(21):1950-8.
Laura B. Ramsey, PhD
Dr. Laura Ramsey completed her undergraduate work in 2004, receiving her BS in chemistry at the University of Northern Iowa in Cedar Falls, IA. She then joined the Molecular, Cellular, Developmental Biology & Genetics Program at the University of Minnesota in Minneapolis, MN, where she studied the role of B cell receptor signaling in autoimmunity and leukemia.
After defending her thesis and receiving her PhD in 2009, Dr. Ramsey began her postdoctoral training with Dr. Mary Relling at St. Jude Children's Research Hospital in Memphis, TN. There she studied pharmacogenomics, and identified genetic variants associated with clearance of the drug methotrexate.
Dr. Ramsey is a member of the Clinical Pharmacogenetics Implementation Consortium (CPIC), and led the 2014 update of the CPIC guideline regarding SLCO1B1 and simvastatin-induced myopathy.
PhD: University of Minnesota, Minneapolis, MN, 2009.
BS: University of Northern Iowa, Cedar Falls, IA, 2004.
Ramsey LB, Janke LJ, Payton MP, Cai X, Paugh SW, Karol SE, Kamdem Kamdem L, Cheng C, Williams RT, Jeha S, Pui C-H, Evans WE, Relling MV. Antileukemic efficacy of continuous vs discontinuous dexamethasone in murine models of acute lymphoblastic leukemia. PLOS ONE. 2015 Aug 7;10(8):e0135134.
Fernandez CA, Smith C, Yang W, Mullighan CG, Qu C, Larsen E, Bowman WP, Liu C, Ramsey LB, Chang TY, Karol SE, Loh ML, Raetz EA, Winick N, Hunger SP, Carroll WL, Jeha S, Pui CH, Evans WE, Devidas M, Relling MV. Genome-wide analysis links NFATC2 with asparaginase hypersensitivity. Blood. 2015 Jul 2;126(1):69-75.
Paugh SW, Bonten EJ, Savic, D, Ramsey LB, Thierfelder WE, Gurung P, Malireddi, RKS, Actis M, Mayasundari A, Min J, Coss DR, Laudermilk LT, Panetta JC, McCorkle JR, Fan Y, Crews KR, Stocco G, Wilkinson MR, Ferreira AM, Cheng C, Yang W, Karol SE, Fernandez CA, Diouf B, Smith C, Hicks JK, Zanut A, Giordanengo A, Crona D, Bianchi JJ, Holmfeldt L, Mullighan CG, den Boer ML, Pieters R, Jeha S, Dunwell TL, Latif F, Bhojwani D, Carroll WL, Pui CH, Myers RM, Guy RK, Kanneganti TD, Relling MV, Evans WE. Epigenetic up-regulation of the NLRP3 inflammasome in leukemia cells causes glucocorticoid resistance by CASP1 cleavage of the glucocorticoid receptor. Nat Genet. 2015 Jun;47(6):607-14.
Bhojwani D, Darbandi R, Pei D, Ramsey LB, Chemaitilly W, Sandlund J, Cheng C, Pui CH, Relling MV, Jeha S, Metzger M. Severe Hypertriglyceridemia During Therapy For Childhood Acute Lymphoblastic Leukemia. European Journal of Cancer. 2014 Oct;50(15):2685-94.
Fernandez C, Smith C, Yang W, Date M, Bashford D, Larsen E, Bowman WP, Liu C, Ramsey LB, Chang T, Turner V, Loh ML, Raetz EA, Winick NJ, Hunger SP, Carroll WL, Onengut-Gumuscu S, Chen WM, Concannon PJ, Rich SS, Scheet P, Jeha S, Pui CH, Evans WE, Devidas M, Relling MV. HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies. Blood. 2014 Aug 21;124(8):1266-76.
Ramsey LB, Johnson SG, Caudle KE, Haidar CE, Voora D, Wilke RA, Maxwell WD, McLeod HL, Krauss RM, Roden DM, Feng Q, Cooper-DeHoff R, Gong L, Klein T, Wadelius M, Niemi M. The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin Pharmacol Ther. 2014 Oct;96(4):423-8.
Ramsey LB, Janke LJ, Edick MJ, Cheng C, Williams RT, Sherr CJ, Evans WE, Relling MV. Host thiopurine methyltransferase status affects mercaptopurine antileukemic effectiveness in a murine model. Pharmacogenet Genomics. 2014;24(5):263-271.
Relling MV, Ramsey LB. Pharmacogenomics of ALL: New insights into treatment toxicity and efficacy. Hematology Am Soc Hematol Educ Program. 2013:126-30, 2013.
Ramsey LB, Panetta JC, Smith C, Yang W, Fan Y, Winick NJ, Martin PL, Cheng C, Devidas M, Pui CH, Evans WE, Hunger SP, Loh M, Relling MV. Genome-wide study of methotrexate clearance replicates SLCO1B1. Blood. 121(6):898-904, 2013.
Wilke RA, Ramsey LB, Johnson SG, Maxwell WD, McLeod HL, Voora D, Krauss RM, Roden DM, Feng Q, Cooper-DeHoff R, Gong L, Klein T, Wadelius M, Niemi M. The Clinical Pharmacogenomics Implementation Consortium (CPIC) guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther. 2012;92(1):112–117.
Senthilkumar Sadhasivam, MD, MPH
is director of Perioperative Pain Service, has clinical interests in regional anesthesia, fetal anesthesia and perioperative pain management. His funded clinical research aims to improve anesthetic outcomes and personalizing pain management. He mentors junior faculty with clinical research, especially pharmacogenetic and pharmacokinetic research to improve perioperative outcomes in children.
Professor, UC Department of Anesthesiology
MBBS: Thanjavur Medical College, India, 1993.
MD: AIIMS, New Delhi, India, 1999.
Residency: Beth Israel Deaconess Medical Center, Harvard University, Boston, MA.
Fellowship: Children's Hospital of Philadelphia, 2004.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462 | TTY:1-513-636-4900
New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479
© 1999-2016 Cincinnati Children's Hospital Medical Center. All rights reserved.